Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-12-05

Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 3]

View source ↗

Summary

Phase 3 study of Reldesemtiv in amyotrophic lateral sclerosis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Reldesemtiv (tirasemtiv)

Snippet

Sponsor: Cytokinetics | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2024-12-05